Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Teijin: Bonalon, Home Care Business Drive Business
November 24, 2008
- Toho: Net Losses due to Bankruptcy of Fuji Biomedix
November 24, 2008
- Meiji Seika: Sales of Generics Up 38.9%
November 24, 2008
- Nihon Chouzai: Investment in Generics Business Depresses Profitability
November 24, 2008
- Ajinomoto: Pharma Sales Up 1.0% to \42.9 Bil.
November 24, 2008
- QOL: Acquisition Boosts Sales by 52%
November 24, 2008
- BUSINESS NEWS IN BRIEF
November 24, 2008
- Wholesale Business Management Seminar
November 24, 2008
- ASKA, Actavis Create Generic Joint Venture Firm in Japan
November 24, 2008
- Santen to Recover Market Share with Tafluprost
November 24, 2008
- DPC Has Increased Use of Generics in over 60 DPC Hospitals: JHA Survey
November 24, 2008
- Shionogi: Rosuvastatin, Doripenem Drive Business
November 17, 2008
- Home Monitoring Improves QOL of CRD Device Recipents
November 17, 2008
- Ono: Sales Down 7.5%, Long-Listed Products Accounting for over 90% of Total Sales
November 17, 2008
- Makers of Self-Monitoring Devices for Blood Glucose Required to Review Package Inserts
November 17, 2008
- Kowa to Make Livalo a Global Product
November 17, 2008
- Precautions for Cold Remedies Required for Children Less than 2 Years Old
November 17, 2008
- Diovan Ranked No. 1 for 2 Consecutive Months: Rep Track Survey
November 17, 2008
- Korosho Council to Promote Public Education on Cancer
November 17, 2008
- Adapalene to Promote Treatment of Acne in Japan: Prof. Kawashima
November 17, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…